Search

Displaying results 4451 - 4460 of 5300 in total
  1. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    MF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.

  2. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.

  3. Drug

    Dialyzable leukocyte extract

    go.drugbank.com/drugs/DB16530
    Investigational

    Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator.

  4. Drug

    MVR-T3011

    go.drugbank.com/drugs/DB17378
    Investigational

    MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1

  5. Drug

    Latrunculin A

    go.drugbank.com/drugs/DB02621
    Investigational

    Latrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer.

  6. Drug

    PI-166

    go.drugbank.com/drugs/DB05859
    Experimental

    PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.

  7. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular deg...

  8. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … , making trofinetide the first and only treatment approved for Rett syndrome in the European Union.

  9. Drug

    Rilpivirine

    go.drugbank.com/drugs/DB08864
    ApprovedInvestigational

    [L31193] While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

    Synonyms: 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
  10. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]